-Increases Sensitivity to Detect Canine Bladder and Prostate Cancers to Over 95 Percent-
Sentinel Biomedical Inc., a comparative health company has recently announced the availability of CADET® BRAF-PLUS, a powerful new add-on for its CADET® BRAF product that provides enhanced detection of the most common form of canine bladder and prostate cancer. Together, these veterinary tools detect over 95 percent of canine bladder and prostate cancers and also enhance the company’s mission to understand more about human cancers.
Sentinel Biomedical’s CADET® BRAF product debuted in 2016 as the first non-invasive, reliable, liquid biopsy approach to aid detection of canine urothelial carcinoma.
Canine urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), is the most common cancer affecting the canine bladder and prostate, diagnosed in more than 80,000 dogs in the U.S. each year. The state-of-the-art molecular CADET® BRAF analyzes free-catch urine to detect 85 percent of cases of canine urothelial carcinoma. The newly available CADET® BRAF PLUS uses the same urine specimen processed for CADET® BRAF to detect urothelial carcinoma cases that are not associated with the CADET® BRAF mutation. Use of CADET® BRAF PLUS takes the overall sensitivity to detect canine UC to over 95 percent. CADET® BRAF-PLUS is recommended as an add-on analysis when the CADET® BRAF mutation is not detected in dogs showing clinical signs of bladder/prostate cancer.
This exciting advancement was made possible through rigorous research by Sentinel Biomedical, in collaboration with Dr. Matthew Breen’s research group at the NC State University College of Veterinary Medicine.